Peter Hersey
The University of Sydney · 670 works · 73,660 citations · h-index 109
Top works
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
- The Immune Landscape of Cancer
- Genomic Classification of Cutaneous Melanoma
- Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group
- Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
- The repertoire of mutational signatures in human cancer
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- Pan-cancer analysis of whole genomes
- Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
- Comprehensive Characterization of Cancer Driver Genes and Mutations
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- Whole-genome landscapes of major melanoma subtypes
- Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
- Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
- PD ‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐ PD ‐1/ PD ‐ L 1 clinical trials
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images